[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342485-105":59,"doc-detail-342485-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-the-molecular-aspects-of-myeloproliferative-neoplasms-associated-with-unusual-site-vein-thrombosis-review-of-the-literature-and-latest-insights","Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis - Review of the Literature and Latest Insights","","Myeloproliferative neoplasms (MPNs) are major drivers of unusual site thrombosis, affecting nearly 40% of patients with conditions such as Budd–Chiari syndrome or portal vein thrombosis. Diagnosis is difficult because classic MPN indicators (e.g., splenomegaly and elevated blood counts) may be masked by portal hypertension or bleeding. New diagnostic advances improve accuracy in classification, while molecular markers are central for both prognosis and assessment. The review emphasizes initiating workup with JAK2 V617F mutation screening and applying a multidisciplinary diagnostic approach. It supports tailored care pathways to reduce hematological and hepatic complications.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-the-molecular-aspects-of-myeloproliferative-neoplasms-associated-with-unusual-site-vein-thrombosis-review-of-the-literature-and-latest-insights/342485/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-the-molecular-aspects-of-myeloproliferative-neoplasms-associated-with-unusual-site-vein-thrombosis-review-of-the-literature-and-latest-insights/342485.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is diagnosing MPNs in unusual site thrombosis cases challenging?","Question",{"text":112,"@type":113},"Common MPN indicators such as spleen enlargement and elevated blood cell counts can be obscured by portal hypertension or bleeding issues.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role do molecular markers play in MPN diagnosis and prognosis?",{"text":117,"@type":113},"Molecular markers are pivotal for both diagnosis and prognosis assessment, complementing clinical criteria such as bone marrow biopsy.",{"name":119,"@type":110,"acceptedAnswer":120},"How should clinicians begin the diagnostic process for splanchnic vein thrombosis with suspected MPN?",{"text":121,"@type":113},"The review recommends initiating the workup with JAK2 V617F mutation screening, followed by a comprehensive, multidisciplinary diagnostic strategy to determine the MPN subtype and guide additional testing.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342485,1790182193,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Review  \nExploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis:  \nReview of the Literature and Latest Insights  \nErika Morsia 1,2,*, Elena Torre 1, Francesco Martini 2,3, Sonia Morè 1,2, Antonella Poloni 1,2, Attilio Olivieri 1,2 and Serena Rupoli 1  \nCitation: Morsia, E.; Torre, E.; Martini, F.; Morè, S.; Poloni, A.; Olivieri, A.; Rupoli, S. Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights. Int. J. Mol. Sci. 2024, 25, 1524. [https://](https://)[ ](https://)[doi.org/10.3390/ijms25031524](doi.org/10.3390/ijms25031524)  \nAcademic Editors: Anna Rita Migliaccio and Ronald Hoffman  \nReceived: 18 December 2023  \nRevised: 18 January 2024  \nAccepted: 22 January 2024  \nPublished: 26 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Hematology Clinic, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy  \n2 Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle Marche,  \n60126 Ancona, Italy  \n3 Clinic of Gastroenterology, Hepatology, and Emergency Digestive Endoscopy, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy  \n* Correspondence: [e.morsia@univpm.it](e.morsia@univpm.it)  \nAbstract: Myeloproliferative neoplasms (MPNs) are the leading causes of unusual site thrombosis, affecting nearly 40% of individuals with conditions like Budd–Chiari syndrome or portal vein thrombosis. Diagnosing MPNs in these cases is challenging because common indicators, such as spleen enlargement and elevated blood cell counts, can be obscured by portal hypertension or bleeding issues. Recent advancements in diagnostic tools have enhanced the accuracy of MPN diagnosis and classification. While bone marrow biopsies remain significant diagnostic criteria, molecular markers now play a pivotal role in both diagnosis and prognosis assessment. Hence, it is essential to initiate the diagnostic process for splanchnic vein thrombosis with a JAK2 V617F mutation screening, but a comprehensive approach is necessary. A multidisciplinary strategy is vital to accurately determine the specific subtype of MPNs, recommend additional tests, and propose the most effective treatment plan. Establishing specialized care pathways for patients with splanchnic vein thrombosis and underlying MPNs is crucial to tailor management approaches that reduce the risk of hematological outcomes and hepatic complications.  \nKeywords: myeloproliferative neoplasms; splanchnic vein thrombosis; cerebral vein thrombosis; clonal hematopoiesis of indeterminate potential  \n1. Introduction  \n1.1. MPNs and Thrombotic Risk  \nThrombosis remains a major problem in patients with myeloproliferative neoplasms (MPNs) . Indeed, this group of diseases, which include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), is characterized by the uncontrolled clonal expansion of multipotent bone marrow progenitors driven by acquired mutations in the JAK2, CALR, and MPL genes [1] . This expansion of the mutated clone initiates an inflammatory response that influences the development of related vascular complications in addition to disease progression [2] .  \nThe prospective analysis of thrombotic events in the European collaboration on lowdose aspirin study (ECLAP) found that cardiovascular events accounted for 45% of allcause mortality in PV at 2.7 years follow-up, compared with hematologic transformation in 13%[3,4] . The risk of thrombosis appears to be highest at the time of initial diagnosis [5] . The rate of arterial and venous thrombosis in MPN","cbCaitE6Y9PeLy17","https://ap.wps.com/l/cbCaitE6Y9PeLy17","pdf",1152077,14,"English","# Abstract\n# Introduction\n## MPNs and Thrombotic Risk\n## MPN and Unusual Site Thrombosis","[{\"question\":\"Why is diagnosing MPNs in unusual site thrombosis cases challenging?\",\"answer\":\"Common MPN indicators such as spleen enlargement and elevated blood cell counts can be obscured by portal hypertension or bleeding issues.\"},{\"question\":\"What role do molecular markers play in MPN diagnosis and prognosis?\",\"answer\":\"Molecular markers are pivotal for both diagnosis and prognosis assessment, complementing clinical criteria such as bone marrow biopsy.\"},{\"question\":\"How should clinicians begin the diagnostic process for splanchnic vein thrombosis with suspected MPN?\",\"answer\":\"The review recommends initiating the workup with JAK2 V617F mutation screening, followed by a comprehensive, multidisciplinary diagnostic strategy to determine the MPN subtype and guide additional testing.\"}]","Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis - Review of the Literature and Latest Insights | PDF",1790046796,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7f6a038167af926cee951619f52a63a.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/693eafceba5d9cb6feab182681711d7b.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/598c02eaba70ca8625cdb57748519851.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0af31f5da46075bc5478ac5df0521060.webp",980,1385]